Newly emerging biomarkers in gastric carcinoma involving ramucirumab monotherapy pinpoint to immunohistochemistry for VEGFR-2 as a promising tool, since the patient showed a high VEGFR-2 score, even if no robust differences have been detected, likely due to a lack of statistical power [122]. The gene discussed is KDR; the disease is gastric carcinoma.